Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-04-11
2006-04-11
Murphy, Joseph (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S139100, C435S007100, C530S300000, C530S350000, C530S387900, C530S388100
Reexamination Certificate
active
07026283
ABSTRACT:
Calcium independent CD81 inhibition of IgE-mediated degranulation in mast cells, particularly through the FcγRIII and FcεRI receptors, is described, as well as methods of inhibiting allergic processes.
REFERENCES:
Tanaka, M., et al., “IgE-Mediated Hypersensitivity and Contact Sensitivity to Multiple Environmental Allergens in Atopic Dermatitis,”Arch. Dermatol., 130(11):1393-1401 (1994) (Abstract only).
Sussman, G. L., and Beezhold D. H., “Allergy to Latex Rubber,”Ann. Intern. Med., 122(1):43-46 (1995).
Kuby, J., “Hypersensitive Reaction,” InImmunology, Second Edition, (NY: W. H. Freeman and Company), pp. 129 and 417-443 (1994).
Maecker, H. T., et al., “CD81 on B Cells Promotes Interleukin 4 Secretion and Antibody Production During T Helper Type 2 Immune Responses,”Proc. Natl. Acad. Sci. USA, 95:2458-2462 (1998).
Maurer, D., et al., “Peripheral Blood Dendritic Cells Express FcεRI as a Complex Composed of FcεRIα-and FcεRIγ-Chains and an Use This Receptor for IgE-Mediated Allergen Presentation,”J. Immun., 607-616 (1996).
Pileri, P., et al., “Binding of Hepatitis C. Virus to CD81,”Science(282):938-941 (1998).
Jouvin, M-H.E., et al., “Differential Control of the Tyrosine Kinases Lyn and Syk by the Two Signaling Chains of the High Affinity Immunoglobulin E Receptor”,The Journal of Biological Chemistry, 269(8):5918-5925 (1994).
Penhallow, R.C., et al., “Temporal Activation of Nontransmembrane Protein-Tyrosine Kinases Following Mast Cell FcεRI Engagement”,The Journal of Biological Chemistry; 270(40) :23362-23365 (1995).
Scharenberg, A.M., et al., “Reconstitution of Interactions Between Tyrosine Kinases and the High Affinity IgE Receptor Which Are Controlled by Receptor Clustering”,The EMBO Journal, 14(14) :3385-3394 (1995).
Lin, S., et al., “The FcεRIβ Subunit Functions as an Amplifier of FcεRIγ-Mediated Cell Activation Signals”,Cell, 85:985-995 (1996).
Paul, W.E., et al., “Lymphokine and Cytokine Production by FcεRI+Cells”,Advances in Immunology, 53:1-29 (1993).
Scharenberg, A.M. and Kinet, J-P., “Early Events in Mast Cell Signal Transduction”,Chem. Immunol., 61:72-87 (1995).
Ravtech, J.V. and Kinet, J-P., “Fc Receptors”,Annu. Rev. Immunol., 9:457-492 (1991).
Shaw, A.S., et al., “Interactions of TCR Tyrosine Based Activation Motifs with Tyrosine Kinases”,Immunology, 7:13-20 (1995).
Choi, O.H., et al., “Calcium Mobilization via Sphingosine Kinase in Signalling by the FcεRI Antigen Receptor”,Nature, 380:634-636 (1996).
Guthmann, M.D., et al., “A Secretion Inhibitory Signal Transduction Molecule on Mast Cells is Another C-Type Lectin”,Proc. Natl. Acad. Sci., 92:9397-9401 (1995).
Katz, H.R., et al., “Mouse Mast Cell gp49B1 Contains Two Immunoreceptor Tyrosine-Based Inhibition Motifs and Suppresses Mast Cell Activation When Coligated with the High-Affinity Fc Receptor for IgE”,Proc. Natl. Acad. Sci., 93:10809-10814 (1996).
Wright, M.D. and Tomlinson, M.G., “The Ins and Outs of the Transmembrane 4 Superfamily”,Immunology Today, 15(12) :588-594 (1994).
Fearon, D.T and Carter, R.H., “The CD19/CR2/TAPA-1 Complex of B Lymphocytes: Linking Natural to Acquired Immunity”,Annu Rev. Immunol. 13:127-149 (1995).
Secrist, H., et al., “Ligation of TAPA-1 (CD81) or Major Histocompatibility Complex Class II in Co-Cultures of Human B and T Lymphocytes Enhances Interleukin-4 Synthesis by Antigen-Specific Cd4′T Cells”,Eur. J. Immunol., 26:1435-1442 (1996).
Todd, S.C., et al., “CD81 Expressed on Human Thymocytes Mediates Integrin Activation and Interleukin 2-Dependent Proliferation”,J. Exp. Med., 184:2055-2060 (1996).
Oren, R., et al., “TAPA-1, the Target of an Antiproliferative Antibody, Defines a New Family of Transmembrane Proteins”,Molecular and Cellular Biology, 10(8) :4007-4015 (1990).
Boismenu, R., et al., “A Role for CD81 in Early T Cell Development”,Science, 271:198-200 (1996).
Imai, T., et al., “Molecular Analyses of the Association of CD4 with Two Members of the Transmembrane 4 Superfamily, CD81 and CD82”,The Journal of Immunology, 155:1229-1239 (1995).
Angelisovà, P., et al., “Association of Four Antigens of the Tetraspans Family (CD37, CD53, TAPA-1, and R2/C33) with MHC Class II Glycoproteins”,Immunogenetics, 39:249-256 (1994).
Mannion, B.A., et al., “Transmembrane-4 Superfamily Proteins CD81 (TAPA-1) , CD82, CD63, and CD53 Specifically Associate with Integrin α4β1(CD49d/CD29)”,The Journal of Immunology, 157 :2039-2047 (1996).
Berditchevski, F., et al., “A Novel Link Between Integrins, Transmembrane-4 Superfamily Proteins (CD63 and CD81) , and Phosphatidylinositol 4-Kinase”,The Journal of Biological Chemistry, 272(5) :2595-2598 (1997).
Ono, M., et al., “Role of the Inositol Phosphatase SHIP in Negative Regulation of The Immune System by the Receptor FcγRIIB”,Nature, 383:263-266 (1996).
Burshtyn, D.N., et al., “Recruitment of Tyrosine Phosphatase HCP by the Killer Cell Inhibitory Receptor”,Immunity, 4:77-85 (1996).
Galli, S.J., “New Concepts About the Mast Cell”,The New England Journal of Medicine, 328(4) :257-265 (1993).
Maecker, H.T. and Levy, S., “Normal Llymphocyte Development but Delayed Humoral Immune Response in CD81-null Mice”,J. Exp. Med., 185(8) :1505-1510 (1997).
Miyazaki, T., et al., “Normal Development But Differentially Altered Proliferative Responses of Lymphocytes in Mice Lacking CD81”,EMBO J., 16(14) :4217-4225 (1997).
Tsitsikov, E.N., et al., “Impaired CD19 Expression and Signaling, Enhanced Antibody Response to Type II T Independent Antigen and Reduction of B-1 Cells in CD81-Deficient Mice”,Proc. Natl. Acad. Sci., USA, 94:10844-10849 (1997).
Andria, M. L., et al., “Genomic Organization and Chromosomal Localization of the TAPA-1 Gene”,The Journal of Immunology, 147(3) :1030-1036 (1991).
Levy, Shoshana, et al., “Structure and Membrane Topology of TAPA-1”,The Journal of Biological Chemistry, 266(22) :14597-14602 (1991).
Benhamou, M., et al., “Protein Tyrosine Kinases in Activation Signal of Human Basophils Through the Immunoglobulin E Receptor Type I”,Journal of Leukocyte Biology, 59:461-470 (1996).
Fleming, Tony J., et al., “Negative Regulation of FcεRI-mediated Degranulation by CD81”,J. Exp. Med., 186(8) :1307-1314 (1997).
Fleming Tony
Kinet Jean-Pierre
Basi Nirmal S.
Beth Israel Deaconess Medical Center Inc.
Hamilton Brook Smith & Reynolds P.C.
Murphy Joseph
LandOfFree
Calcium-independent negative regulation by CD81 of receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium-independent negative regulation by CD81 of receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium-independent negative regulation by CD81 of receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3601818